Research in the USA indicates that the current treatment paradigm for metastatic castration-resistant prostate cancer is not cost effective, largely owing to the high cost of treatment strategies and limited improvement in survival. The analysis evaluated the costs and progression-free survival associated...
The aim of this review is to report on the current status of prostate-specific membrane antigen (PSMA)-directed theranostics in prostate cancer (PC) patients. The value of68Ga-PSMA-directed PET imaging as a diagnostic procedure for primary and recurrent PC as well as the role of evolving PSM...
Pharmacological Treatment Options In Development PURPOSE OF REVIEW: First, to describe the current pharmacological treatment options for peripheral and central vestibular, cerebellar, and ocular motor dis... RD Hite,PE Morris 被引量: 17发表: 2001年 Gynecomastia in Patients with Prostate Cancer: A Sys...
treatment with curative intent, as well as castration-resistant prostate cancer, have extensively evolved with the introduction and approval of several new agents including sipuleucel-T, radium-223, abiraterone, enzalutamide and cabazitaxel, all of which have shown significant improvement on overall ...
For men who have hormone-refractory prostate cancer, current treatment options are somewhat limited, with docetaxel the only agent showing a significant prolongation of survival. Several groups have investigated therapeutic approaches involving stimulation of an immune response against progressive prostate canc...
However, during the treatment of anti-androgen, despite of initial response, the patients almost ...
Current, new and novel therapy for castration-resistant prostate cancer. Androgen deprivation therapy is the standard of care for the initial treatment of metastatic prostate cancer. However, the majority of these patients live ... JM Gaya,Y Ahallal,R Sanchez-Salas,... - 《Expert Rev Anticancer...
Opening with a critical assessment of the controversies that abound in relation to the treatment of every stage of prostate cancer, this publication focuses on the evaluation of new pharmacological developments in prostates cancer treatment. The first study investigates the effects of neoadjuvant androgen...
Current Status of Thalidomide and CC-5013 in the Treatment of Metastatic Prostate Cancer, Angiogenesis Inhibition in the Treatment of Prostate Cancer, Agents... P Doi - Anti-Cancer Agents in Medicinal Chemistry 被引量: 0发表: 0年 Current Concepts in the Etiology and Treatment of Behçet Diseas...
Management of Biochemical Recurrence After Primary Treatment of Prostate Cancer: A Systematic Review of the Literature AbstractContext Despite excellent cancer control with the treatment of localized prostate cancer (PCa), some men will experience a recurrence of disease. T... Sanoj Punnen and Matthew...